Expanded Access Program for Lorcaserin (Belviq)

Go Back to All Clinical Trials

Expanded Access Program for Lorcaserin (Belviq)

Brief description of study

The purpose of this extended access program is to provide continued access to lorcaserin for Dravet syndrome and other epilepsy patients who were being treated with lorcaserin before the US Food and Drug Administration (FDA) withdrew approval of the drug and who may have benefited from the treatment. Lorcaserin is not approved by the FDA or any other regulatory agency for any conditions or diseases. As lorcaserin has not been studied in Dravet syndrome or other epilepsies, there is no guarantee that lorcaserin will improve your seizure control.

Clinical Study Identifier: s20-00271

Principal Investigator: Orrin Devinsky.

Other Investigators: Erin K Conway, Andrew Charles Christiana, Daniel Friedman.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies